As you will be aware, The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer.
Following information received from the company this appraisal has been scheduled into the work programme. The appraisal is anticipated to begin in mid-July 2022.